Being diagnosed with myelodysplastic syndrome (MDS) can be a shock, particularly when you may never have heard of it. MDS UK has now produced a new edition of the MDS patient booklet, created in cooperation with our colleagues from Leukaemia Care and Bloodwise. At MDS UK, we felt there was an urgent need to revise the […]
Read full story
Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Vidaza and Azacitidine are the same drug Azacitidine is the official generic and non-proprietary name given to the drug active ingredient while Vidaza is its trade name. The drug is widely available in the UK for the treatment […]
Read full story
Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Cell therapies, sometimes called “living therapies”, are an especially promising and rapidly growing area of cancer research. One approach that’s been pioneered by Memorial Sloan Kettering researchers, led by investigator Michel Sadelain, is called CAR-T cell immunotherapy. This […]
Read full story
The MDS UK Committee is pleased to welcome two new members to the charity team: Lizzie Marshall, and Chris Fryer. Both Lizzie and Chris have experience in the Non-Profit and Charity Sector. Lizzie is a trainee psychotherapist with a background in the performing arts. She works supporting vulnerable people with learning difficulties alongside her new […]
Read full story
- SUB-TYPE OF MDS:Higher risk MDS, CMML, low blast count AML
- SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
- NAME OF DRUG: Azacitidine, Pevonedistat
- SUB-TYPE OF MDS:Previously untreated higher-risk MDS, AML or CMML
- SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
- NAME OF DRUG: Glasdegib, Azacitidine
- SUB-TYPE OF MDS:High risk MDS and AML, not suitable for induction chemotherapy or haemopoietic stem cell transplant
- SEVERITY OF MDS: High Risk MDS
- NAME OF DRUG: PDR001, MBG453, Decitabine
- SUB-TYPE OF MDS: High Risk MDS RAEB-2 and Acute Myeloid Leukaemia Patients Unsuitable for Allogeneic Haematological Stem Cell Transplant
- SEVERITY OF MDS: High Risk MDS
- NAME OF DRUG: B7.1 (CD80)/IL-2 Immune Gene Therapy
- SUB-TYPE OF MDS: Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome with an IDH1 R132 mutation
- SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
- NAME OF DRUG: FT-2102
This is an urgent appeal for stem cell donors, for a Dad who was diagnosed in July 2018 with a high-risk form of MDS, Myelodysplastic Syndromes, a rare form of blood cancer, that can progress to leukaemia. Damian is a father of 7 lovely children – aged 4 to 27. Damian was told that without treatment, […]
Read full story